FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry, in particular to an isolated antibody or its antigen-binding fragment that is specifically associated with a human GITR protein. Also disclosed is pharmaceutical composition containing said antibody or its fragment, nucleic acid, encoding said antibody or its fragment, an expression vector comprising said nucleic acid, host cell comprising said vector. Invention discloses method of producing above antibody or its antigen-binding fragment, as well as a method for enhancing the immune response in human upon administration of said antibody or its antigen-binding fragment.
EFFECT: invention has the ability to specifically bind to GITR protein, thereby enhancing the immune response in humans.
26 cl, 8 ex, 2 dwg, 9 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-GITR ANTIBODIES | 2010 |
|
RU2595409C2 |
| ANTIBODIES TO PROGRAMMED CELL DEATH PROTEIN 1 | 2018 |
|
RU2812915C2 |
| HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED DEATH 1 (PD-1) PROTEIN AND CANCER TREATMENT METHOD USING ANTI-PD-1-ANTIBODIES SEPARATELY OR COMBINED WITH OTHER IMMUNOTHERAPEUTIC AGENTS | 2013 |
|
RU2599417C2 |
| NOVEL ANTIBODIES | 2008 |
|
RU2490277C2 |
| ANTI-PTK7 ANTIBODY-DRUG CONJUGATES | 2015 |
|
RU2708075C2 |
| ANTIBODIES TO THE RELATED CANCER-EMBRYONIC ANTIGEN CELL ADHESION MOLECULE (CEACAM) | 2012 |
|
RU2650869C2 |
| HUMANISED ANTI-TGF-BETA-ANTIBODY | 2005 |
|
RU2386638C2 |
| HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED DEATH 1 (PD-1) PROTEIN AND CANCER TREATMENT METHOD USING ANTI-PD-1-ANTIBODIES SEPARATELY OR COMBINED WITH OTHER IMMUNOTHERAPEUTIC AGENTS | 2006 |
|
RU2406760C2 |
| HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR PROGRAMMED CELL DEATH 1 (PD1) PROTEIN AND METHODS OF TREATING CANCER WITH USING ANTI-PD1 ANTIBODIES EITHER INDIVIDUALLY, OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTIC AGENTS | 2006 |
|
RU2494107C2 |
| INTERLEUKIN-13-BINDING PROTEINS | 2012 |
|
RU2605327C2 |
